Artificial Organs and Bionics Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Artificial Organs and Bionics Market Report is Segmented by Device Type (Artificial Organs [Artificial Heart, Artificial Kidney, and More] and Bionics [Vision Bionics, Ear Bionics, and More]), Technology (Implantable Devices and Wearable Devices), End User (Hospitals & Surgical Centres, Home-Care and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Artificial Organs And Bionics Market Size and Share

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Compare market size and growth of Artificial Organs And Bionics Market with other markets in Healthcare Industry

Artificial Organs And Bionics Market Analysis by Mordor Intelligence

The artificial organs and bionics market is worth USD 31.99 billion in 2025 and is forecast to reach USD 45.29 billion in 2030, advancing at a 7.20% CAGR. Size expansion is being shaped by converging breakthroughs in biomaterials, miniaturized electronics, and 3-D bioprinting, all of which compress development timelines and lift clinical adoption of cardiovascular, renal, and neuro-prosthetic devices. Stretched transplant waiting lists and fast-track regulatory programs are spurring investment in total artificial hearts, wearable artificial kidneys, and next-generation brain–computer interfaces. Defense-funded limb-restoration programs have unlocked neural-interface know-how that is flowing into civilian solutions, while insurers’ gradual acceptance of home-based bionic therapies broadens the treated population. Supply-chain fragilities surrounding rare-earth sensors and high-end chips remain a watchpoint, yet growing regional manufacturing footprints in Asia-Pacific are easing part of that exposure.

Key Report Takeaways

  • By device type, artificial organs led with 70.26% revenue share in 2024; bionics is projected to expand at an 8.25% CAGR to 2030. 
  • By technology, wearable and extracorporeal systems held 55.53% of the artificial organs and bionics market share in 2024, while implantable systems are slated for the highest CAGR at 9.35% through 2030. 
  • By end user, hospitals and surgical centers accounted for 47.82% of the artificial organs and bionics market size in 2024, whereas home-care and ambulatory settings are growing at 9.26% CAGR during 2025-2030. 
  • By geography, North America retained 38.82% share of the artificial organs and bionics market in 2024, while Asia-Pacific is forecast to register the fastest regional CAGR at 10.62% to 2030.

Segment Analysis

By Device Type: Artificial Organs Lead Despite Bionic Acceleration

Artificial organs commanded 70.26% of the artificial organs and bionics market in 2024 as transplant shortages sustained demand for ventricular assist devices and emerging bioartificial kidneys. Bionics is tracking an 8.25% CAGR to 2030, aided by miniaturised brain–computer interfaces that now facilitate speech and fine-motor control. The artificial organs and bionics market size for heart devices alone is projected to expand at 7.8% CAGR, supported by FDA breakthrough tags for titanium total artificial hearts. 

Clinical momentum is evident in renal assist systems where Roivios obtained breakthrough designation and is preparing U.S. pivotal trials. Bio-printed liver constructs and gene-edited pig livers are progressing through early-phase studies, signalling pipeline depth. Neuro-bionics growth is amplified by AI-driven control algorithms that adapt in milliseconds to user intent. Collectively, these innovations anchor long-term revenue visibility across the artificial organs and bionics market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

By Technology: Implantable Systems Gain Ground Through Innovation

Wearable and extracorporeal platforms held 55.53% share in 2024, yet implantables are climbing faster at 9.35% CAGR as biocompatible polymers, rechargeable batteries, and thin-film electronics enable long-term in-body operation. Cochlear-implant pioneers have demonstrated totally implantable devices that obviate external microphones, strengthening the artificial organs and bionics market proposition for discreet therapies. 

Leadless pacemakers such as Abbott’s AVEIR DR have shown 98.3% implantation success, reinforcing physician confidence[2]Abbott Laboratories, “AVEIR DR Clinical Data,” abbott.com. Externally, AI-enhanced hearing aids can now distinguish speech from 50 dB of background noise, extending wearable device relevance. Integration of wireless charging with fully implanted LVADs removes percutaneous cables, reducing infection risk and improving quality of life. Such cross-pollination of ideas keeps investment flowing into the artificial organs and bionics market.

By End User: Home-Care Transformation Drives Growth

Hospitals held 47.82% share in 2024, yet home-care and ambulatory settings are projected to expand at 9.26% CAGR as device makers embed Bluetooth Low-Energy chips, cloud analytics, and AI-driven alerts. The artificial organs and bionics market size for outpatient channels is expected to surpass USD 10 billion by 2030, underpinned by reimbursement reforms that now cover remote programming of cochlear implants and pacemakers. 

The Department of Veterans Affairs is piloting portable exoskeletons that users calibrate via smartphone, demonstrating how remote monitoring shortens inpatient rehab[3]Department of Veterans Affairs, “FY 2025 Prosthetics Research Projects,” research.va.gov. Private clinics such as Open Bionics service centers support custom socket fitting and firmware updates, reinforcing a distributed care model. Advances in wireless power transfer and cloud-based dashboards are therefore re-shaping utilisation patterns across the artificial organs and bionics market.

Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Note: Segment shares of all individual segments available upon report purchase

Geography Analysis

North America retained 38.82% share of the artificial organs and bionics market in 2024 on the back of an established FDA fast-track framework and robust venture funding. Investors topped USD 2 billion in disclosed U.S. deals during 2024, half of which went to cardiac and neuro-prosthesis start-ups. The region’s mature reimbursement infrastructure continues to favour early adoption, yet price sensitivity is rising as payers scrutinise cost-effectiveness.

Asia-Pacific is the fastest-growing region with a 10.62% CAGR, catalysed by Japan’s universal artificial blood that maintains two-year shelf life across all blood types. China’s triple-integrated brain-spine interface enabled paraplegic patients to regain over-ground walking within weeks, positioning domestic players at the cutting edge of neuro-prosthetics. Pediatric device innovation is also notable: a 45-gram artificial heart designed for small children filled a vital niche, reinforcing regional clinical leadership.

Europe sustains a technology leadership role through companies such as Carmat, whose Aeson artificial heart received CE marking as a bridge-to-transplant therapy. German transplant centres reported the first fully implantable artificial-heart discharge to home care, broadening real-world validation. Parallel initiatives in organ-preservation perfusion systems further tighten the supply–demand gap for donor organs, keeping Europe firmly inside the high-innovation quadrant of the artificial organs and bionics market.

Growth Rate
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.

Competitive Landscape

The artificial organs and bionics market is moderately fragmented: the top five firms hold a significant revenue, leaving room for nimble specialists. Johnson & Johnson’s USD 16.6 billion take-over of Abiomed underscores the strategic value of proven cardiac platforms. BD’s USD 4.2 billion acquisition of Edwards’ Critical Care unit and Teleflex’s EUR 760 million (USD 878.2 million) purchase of BIOTRONIK’s vascular assets illustrate ongoing portfolio concentration.

Challenger brands are scaling quickly. BiVACOR secured USD 13 million to advance its lightweight titanium artificial heart that delivers pulsatile flow using a magnetically levitated rotor. Synchron’s endovascular brain-computer interface circumvents open-brain surgery, earning FDA investigational-device exemption and fostering differentiation on safety. eGenesis is moving 10-gene-edited pig organs into first-in-human trials after promising non-human primate data, widening competitive parameters.

Incumbents maintain an edge in scale manufacturing and regulatory know-how, yet smaller innovators exploit agility to capture niches such as pediatric hearts and fully implantable cochlear systems. AI-powered hearing aids, augmented-AI exoskeletons, and next-generation wireless LVADs exemplify how software capabilities now shape hardware leadership across the artificial organs and bionics market.

Artificial Organs And Bionics Industry Leaders

  1. Abiomed Inc

  2. Boston Scientific Corporation

  3. Ossur

  4. Baxter International

  5. Medtronic plc

  6. *Disclaimer: Major Players sorted in no particular order
Artificial Organs And Bionics Market Concentration
Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0.
Need More Details on Market Players and Competitors?
Download PDF

Recent Industry Developments

  • May 2025: OrganOx raised new funding from Intuitive Ventures and Terumo Ventures to expand its normothermic liver perfusion platform, now used in more than 5,000 transplant procedures.
  • March 2025: BiVACOR reported a patient surviving 105 days on its titanium total artificial heart before receiving a donor organ, setting a durability record for the technology.
  • February 2025: Abbott obtained CE Mark for AVEIR DR, the first dual-chamber leadless pacemaker system.

Table of Contents for Artificial Organs And Bionics Industry Report

1. Introduction

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2. Research Methodology

3. Executive Summary

4. Market Landscape

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidence Of Chronic Organ Failure & Disabilities
    • 4.2.2 Scarcity Of Donor Organs
    • 4.2.3 Rapid Biomaterial, Micro-Electronics & 3-D Bio-Printing Advances
    • 4.2.4 Defence-Funded Limb-Restoration Programmes (Post-2024)
    • 4.2.5 Fast-Track Regulatory Pathways (FDA BTD, EU MDR Art 117)
  • 4.3 Market Restraints
    • 4.3.1 High Procedure & Device Cost
    • 4.3.2 Biocompatibility Issues & Device Malfunctions
    • 4.3.3 Supply-Chain Fragility Of Rare-Earth Sensors & Chips
  • 4.4 Technological Outlook
  • 4.5 Porter's Five Forces
    • 4.5.1 Threat of New Entrants
    • 4.5.2 Bargaining Power of Buyers
    • 4.5.3 Bargaining Power of Suppliers
    • 4.5.4 Threat of Substitutes
    • 4.5.5 Intensity of Rivalry

5. Market Size & Growth Forecasts (Value, USD)

  • 5.1 By Device Type
    • 5.1.1 Artificial Organs
    • 5.1.1.1 Artificial Heart
    • 5.1.1.2 Artificial Kidney
    • 5.1.1.3 Artificial Lungs
    • 5.1.1.4 Artificial Liver
    • 5.1.1.5 Artificial Pancreas
    • 5.1.1.6 Others
    • 5.1.2 Bionics
    • 5.1.2.1 Vision Bionics
    • 5.1.2.2 Ear Bionics
    • 5.1.2.3 Orthopedic Bionics
    • 5.1.2.4 Cardiac Bionics
    • 5.1.2.5 Neural Bionics
  • 5.2 By Technology
    • 5.2.1 Implantable Devices
    • 5.2.2 Wearable / Extracorporeal Devices
  • 5.3 By End User
    • 5.3.1 Hospitals & Surgical Centres
    • 5.3.2 Specialty & Rehabilitation Clinics
    • 5.3.3 Home-care & Ambulatory Settings
    • 5.3.4 Military & Veterans Care Systems
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 South Korea
    • 5.4.3.5 Australia
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. Competitive Landscape

  • 6.1 Market Concentration
  • 6.2 Market Share Analysis
  • 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Business Segments, Financials, Headcount, Key Information, Market Rank, Market Share, Products and Services, and analysis of Recent Developments)
    • 6.3.1 Abbott Laboratories
    • 6.3.2 Abiomed
    • 6.3.3 Asahi Kasei Medical
    • 6.3.4 Baxter International
    • 6.3.5 Berlin Heart
    • 6.3.6 Boston Scientific Corporation
    • 6.3.7 Cochlear Ltd
    • 6.3.8 CYBERDYNE
    • 6.3.9 Ekso Bionics
    • 6.3.10 Edwards Lifesciences
    • 6.3.11 Getinge AB
    • 6.3.12 MED-EL
    • 6.3.13 Medtronic plc
    • 6.3.14 Ossur
    • 6.3.15 Ottobock
    • 6.3.16 Second Sight Medical
    • 6.3.17 SynCardia Systems
    • 6.3.18 Sonova
    • 6.3.19 Zimmer Biomet

7. Market Opportunities & Future Outlook

  • 7.1 White-Space & Unmet-Need Assessment
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Global Artificial Organs And Bionics Market Report Scope

As per the scope of the report, artificial organs are mechanical devices that can temporarily or permanently substitute for a body organ. These devices can replicate or augment the natural function of the organ. Bionics refers to the replacement or improvement of body parts by mechanical kinds. The Artificial Organs and Bionics Market is segmented by Type (Artificial Organ and Bionics), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.

By Device Type Artificial Organs Artificial Heart
Artificial Kidney
Artificial Lungs
Artificial Liver
Artificial Pancreas
Others
Bionics Vision Bionics
Ear Bionics
Orthopedic Bionics
Cardiac Bionics
Neural Bionics
By Technology Implantable Devices
Wearable / Extracorporeal Devices
By End User Hospitals & Surgical Centres
Specialty & Rehabilitation Clinics
Home-care & Ambulatory Settings
Military & Veterans Care Systems
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
By Device Type
Artificial Organs Artificial Heart
Artificial Kidney
Artificial Lungs
Artificial Liver
Artificial Pancreas
Others
Bionics Vision Bionics
Ear Bionics
Orthopedic Bionics
Cardiac Bionics
Neural Bionics
By Technology
Implantable Devices
Wearable / Extracorporeal Devices
By End User
Hospitals & Surgical Centres
Specialty & Rehabilitation Clinics
Home-care & Ambulatory Settings
Military & Veterans Care Systems
Geography
North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
South Korea
Australia
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Key Questions Answered in the Report

What is the projected value of the artificial organs and bionics market by 2030?

The market is expected to reach USD 45.29 billion in 2030 on a 7.20% CAGR trajectory.

Which segment currently dominates the artificial organs and bionics market?

Artificial organs lead with 70.26% device-type share, driven by critical demand in cardiac and renal support.

Why is Asia-Pacific the fastest-growing regional market?

Breakthroughs such as Japan’s universal artificial blood and China’s brain-spine interfaces, combined with rising healthcare investment, propel a 10.62% CAGR through 2030.

How are implantable systems gaining traction over wearable devices?

Advances in biocompatible materials, wireless charging, and miniaturised electronics enable fully internalised solutions that are growing at 9.35% CAGR.

What are the main challenges limiting broader adoption?

High procedure costs, biocompatibility hurdles, and supply-chain dependence on rare-earth sensors continue to temper growth despite strong technology momentum.

Which recent regulatory milestone could reshape the competitive landscape?

The FDA’s approval of first-in-human trials for gene-edited pig organs signals a potential long-range solution to organ scarcity and a new competitive frontier.

Page last updated on: June 15, 2025

Artificial Organs And Bionics Market Report Snapshots